Key facts
- Biomotum’s last known valuation is $9.5M (Jul 2023).
- It has raised $3.5M across 1 recorded rounds; the latest was Seed Round ($660K) in Oct 2020.
- Notable investors include Creative Destruction Lab, MassChallenge, National Institutes of Health, Portland Seed Fund, Elevate Capital — 17 tracked in total.
- Biomotum has filed 3 Form Ds with the SEC since 2020, most recently Mar 2022 ($200K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Biomotum
Funding rounds
1 roundsAbout Biomotum
Developer of robotic exoskeletons designed to address the rapidly increasing number of people with poor health due to difficulty walking. The company's connected, wearable systems combine the benefits of advanced assistive technology and deliver an easy-to-use therapeutic system that includes real-time training insights, tele-rehab compatibility, and embedded progress reporting, enabling individuals affected by neurologic disorders, including stroke and cerebral palsy.
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2019
- Employees
- 4
- Website
- biomotum.com/
- Ownership
- Privately Held (backing)
Biomotum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biomotum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biomotum in its N-PORT filings yet. We sweep new filings monthly.